These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 22591184)

  • 1. Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis.
    Grønbaek H; Sandahl TD; Mortensen C; Vilstrup H; Møller HJ; Møller S
    Aliment Pharmacol Ther; 2012 Jul; 36(2):173-80. PubMed ID: 22591184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS.
    Holland-Fischer P; Grønbæk H; Sandahl TD; Moestrup SK; Riggio O; Ridola L; Aagaard NK; Møller HJ; Vilstrup H
    Gut; 2011 Oct; 60(10):1389-93. PubMed ID: 21572121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macrophage activation is a prognostic parameter for variceal bleeding and overall survival in patients with liver cirrhosis.
    Waidmann O; Brunner F; Herrmann E; Zeuzem S; Piiper A; Kronenberger B
    J Hepatol; 2013 May; 58(5):956-61. PubMed ID: 23333526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macrophage serum markers in pneumococcal bacteremia: Prediction of survival by soluble CD163.
    Møller HJ; Moestrup SK; Weis N; Wejse C; Nielsen H; Pedersen SS; Attermann J; Nexø E; Kronborg G
    Crit Care Med; 2006 Oct; 34(10):2561-6. PubMed ID: 16915112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Measurement of hepatic venous pressure gradient in liver cirrhosis: relationship with the status of cirrhosis, varices, and ascites in Korea].
    Kim MY; Baik SK; Suk KT; Yea CJ; Lee IY; Kim JW; Cha SH; Kim YJ; Um SH; Han KH
    Korean J Hepatol; 2008 Jun; 14(2):150-8. PubMed ID: 18617762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension.
    La Mura V; Reverter JC; Flores-Arroyo A; Raffa S; Reverter E; Seijo S; Abraldes JG; Bosch J; García-Pagán JC
    Gut; 2011 Aug; 60(8):1133-8. PubMed ID: 21427197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in fat mass correlate with changes in soluble sCD163, a marker of mature macrophages, in patients with CKD.
    Axelsson J; Møller HJ; Witasp A; Qureshi AR; Carrero JJ; Heimbürger O; Bárány P; Alvestrand A; Lindholm B; Moestrup SK; Stenvinkel P
    Am J Kidney Dis; 2006 Dec; 48(6):916-25. PubMed ID: 17162146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macrophage activation marker soluble CD163 may predict disease progression in hepatocellular carcinoma.
    Kazankov K; Rode A; Simonsen K; Villadsen GE; Nicoll A; Møller HJ; Lim L; Angus P; Kronborg I; Arachchi N; Gorelik A; Liew D; Vilstrup H; Frystyk J; Grønbæk H
    Scand J Clin Lab Invest; 2016; 76(1):64-73. PubMed ID: 26549495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis.
    Ferlitsch M; Reiberger T; Hoke M; Salzl P; Schwengerer B; Ulbrich G; Payer BA; Trauner M; Peck-Radosavljevic M; Ferlitsch A
    Hepatology; 2012 Oct; 56(4):1439-47. PubMed ID: 22532296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Macrophage activation marker, soluble CD163, is an independent predictor of short-term mortality in patients with cirrhosis and bacterial infection.
    Tornai T; Vitalis Z; Sipeki N; Dinya T; Tornai D; Antal-Szalmas P; Karanyi Z; Tornai I; Papp M
    Liver Int; 2016 Nov; 36(11):1628-1638. PubMed ID: 27031405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma.
    Waidmann O; Köberle V; Bettinger D; Trojan J; Zeuzem S; Schultheiß M; Kronenberger B; Piiper A
    J Hepatol; 2013 Oct; 59(4):769-79. PubMed ID: 23792028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The macrophage activation marker sCD163 combined with markers of the Enhanced Liver Fibrosis (ELF) score predicts clinically significant portal hypertension in patients with cirrhosis.
    Sandahl TD; McGrail R; Møller HJ; Reverter E; Møller S; Turon F; Hernández-Gea V; Bendtsen F; Vilstrup H; Garcia-Pagan JC; Grønbaek H
    Aliment Pharmacol Ther; 2016 Jun; 43(11):1222-31. PubMed ID: 27061098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral artery disease is associated with a high CD163/TWEAK plasma ratio.
    Moreno JA; Dejouvencel T; Labreuche J; Smadja DM; Dussiot M; Martin-Ventura JL; Egido J; Gaussem P; Emmerich J; Michel JB; Blanco-Colio LM; Meilhac O
    Arterioscler Thromb Vasc Biol; 2010 Jun; 30(6):1253-62. PubMed ID: 20299688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble CD163, a specific macrophage activation marker, is decreased by anti-TNF-α antibody treatment in active inflammatory bowel disease.
    Dige A; Støy S; Thomsen KL; Hvas CL; Agnholt J; Dahlerup JF; Møller HJ; Grønbaek H
    Scand J Immunol; 2014 Dec; 80(6):417-23. PubMed ID: 25346048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble CD163 is an indicator of liver inflammation and fibrosis in patients chronically infected with the hepatitis B virus.
    Dultz G; Gerber L; Farnik H; Berger A; Vermehren J; Pleli T; Zeuzem S; Piiper A; Kronenberger B; Waidmann O
    J Viral Hepat; 2015 Apr; 22(4):427-32. PubMed ID: 25181653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble CD163 in young sickle cell disease patients and their trait siblings: a biomarker for pulmonary hypertension and vaso-occlusive complications.
    Tantawy AA; Adly AA; Ismail EA
    Blood Coagul Fibrinolysis; 2012 Oct; 23(7):640-8. PubMed ID: 22885767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Macrophage activation marker soluble CD163 and non-alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery.
    Kazankov K; Tordjman J; Møller HJ; Vilstrup H; Poitou C; Bedossa P; Bouillot JL; Clement K; Grønbaek H
    J Gastroenterol Hepatol; 2015 Aug; 30(8):1293-300. PubMed ID: 25772748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment.
    Laursen TL; Wong GL; Kazankov K; Sandahl T; Møller HJ; Hamilton-Dutoit S; George J; Chan HL; Grønbaek H
    J Gastroenterol Hepatol; 2018 Feb; 33(2):484-491. PubMed ID: 28618015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.
    Ripoll C; Groszmann R; Garcia-Tsao G; Grace N; Burroughs A; Planas R; Escorsell A; Garcia-Pagan JC; Makuch R; Patch D; Matloff DS; Bosch J;
    Gastroenterology; 2007 Aug; 133(2):481-8. PubMed ID: 17681169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum markers of macrophage activation in pre-eclampsia: no predictive value of soluble CD163 and neopterin.
    Kronborg CS; Knudsen UB; Moestrup SK; Allen J; Vittinghus E; Møller HJ
    Acta Obstet Gynecol Scand; 2007; 86(9):1041-6. PubMed ID: 17712642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.